Gilead 3Q 3Q Revenues: $1.9 billion (+8%) 3Q Earnings: $702.2 million (+5%) YTD Revenues: $6.0 billion (+20%) YTD Earnings: $2.3 billion (+24%) Comments: Product sales were up 13% to $1.9 billion in the quarter. Antiviral product sales were $1.7 billion (+12%), with Atripla sales up 23% to $742.7 million, Truvada sales up 8% to $668.7 million, and Viread sales up 9% to $184.3 million. Sales of Letairis for the treatment of pulmonary arterial hypertension were up 26% to $60.4 milli...